JP Morgan Initiates BioCryst Pharmaceuticals At Overweight

Analysts at JP Morgan initiated coverage on shares of BioCryst Pharmaceuticals

with a Overweight rating. The target price for BioCryst Pharmaceuticals is set to $20. BioCryst Pharmaceuticals shares have surged 136.70% over the past 52 weeks, while the S&P 500 index has gained 12.49% in the same period. BioCryst Pharmaceuticals' shares surged 4.19% to $13.44 in pre-market trading.